monoamine oxidase inhibitors

Summary

Summary: A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Top Publications

  1. pmc Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Glen B Baker
    J Psychiatry Neurosci 32:313-5. 2007
  2. ncbi Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 13:855-70. 2008
  3. pmc An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid
    Thomas M Polasek
    Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia
    Br J Clin Pharmacol 61:570-84. 2006
  4. ncbi Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors
    Francisco López-Muñoz
    Neuropsychopharmacology Unit, Department of Pharmacology, Faculty of Medicine, University of Alcala, Madrid, Spain
    J Clin Psychopharmacol 27:555-9. 2007
  5. ncbi The therapeutic potential of monoamine oxidase inhibitors
    Moussa B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases
    Nat Rev Neurosci 7:295-309. 2006
  6. ncbi trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1
    Dawn M Z Schmidt
    Department of Chemistry, B120 Levine Science Research Center, Box 90317, Duke University, Durham, North Carolina 27708, USA
    Biochemistry 46:4408-16. 2007
  7. ncbi Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
    Robert A Hauser
    Parkinsons s Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA
    Mov Disord 24:564-73. 2009
  8. ncbi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
    O Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Lancet 365:947-54. 2005
  9. ncbi Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors
    Gabriela da S Sant' Anna
    Laboratorio de Neurotoxicidade e Psicofarmacologia, Departamento de Quimica, Centro de Ciencias Naturais e Exatas, Universidade Federal de Santa Maria, 97 105 900, Santa Maria, RS, Brazil
    Bioorg Med Chem Lett 19:546-9. 2009
  10. ncbi Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's di
    Irene Bolea
    Departament de Bioquı́mica i Biologı́a Molecular, Facultat de Medicina, Institut de Neurociencies, Universitat Autonoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
    J Med Chem 54:8251-70. 2011

Detail Information

Publications259 found, 100 shown here

  1. pmc Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Glen B Baker
    J Psychiatry Neurosci 32:313-5. 2007
  2. ncbi Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 13:855-70. 2008
    b>Monoamine oxidase inhibitors (MAOIs) currently have a "bad rap" and are thus infrequently used in psychopharmacology, even by experienced clinicians...
  3. pmc An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid
    Thomas M Polasek
    Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia
    Br J Clin Pharmacol 61:570-84. 2006
    ..To characterize potential mechanism-based inactivation (MBI) of major human drug-metabolizing cytochromes P450 (CYP) by monoamine oxidase (MAO) inhibitors, including the antitubercular drug isoniazid...
  4. ncbi Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors
    Francisco López-Muñoz
    Neuropsychopharmacology Unit, Department of Pharmacology, Faculty of Medicine, University of Alcala, Madrid, Spain
    J Clin Psychopharmacol 27:555-9. 2007
  5. ncbi The therapeutic potential of monoamine oxidase inhibitors
    Moussa B H Youdim
    Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases
    Nat Rev Neurosci 7:295-309. 2006
    b>Monoamine oxidase inhibitors were among the first antidepressants to be discovered and have long been used as such...
  6. ncbi trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1
    Dawn M Z Schmidt
    Department of Chemistry, B120 Levine Science Research Center, Box 90317, Duke University, Durham, North Carolina 27708, USA
    Biochemistry 46:4408-16. 2007
    ..We previously assessed monoamine oxidase inhibitors (MAOIs) for their ability to inhibit the reaction catalyzed by LSD1 [Lee, M. G., et al. (2006) Chem...
  7. ncbi Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
    Robert A Hauser
    Parkinsons s Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA
    Mov Disord 24:564-73. 2009
    ..This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD...
  8. ncbi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
    O Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Lancet 365:947-54. 2005
    ..This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations...
  9. ncbi Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors
    Gabriela da S Sant' Anna
    Laboratorio de Neurotoxicidade e Psicofarmacologia, Departamento de Quimica, Centro de Ciencias Naturais e Exatas, Universidade Federal de Santa Maria, 97 105 900, Santa Maria, RS, Brazil
    Bioorg Med Chem Lett 19:546-9. 2009
    ....
  10. ncbi Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's di
    Irene Bolea
    Departament de Bioquı́mica i Biologı́a Molecular, Facultat de Medicina, Institut de Neurociencies, Universitat Autonoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
    J Med Chem 54:8251-70. 2011
    ..Overall, the results suggest that the new compounds are promising multitarget drug candidates with potential impact for Alzheimer's disease therapy...
  11. ncbi Current place of monoamine oxidase inhibitors in the treatment of depression
    Kenneth I Shulman
    Professor, Department of Psychiatry, Faculty of Medicine, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    CNS Drugs 27:789-97. 2013
    ..search of OvidSP Medline and PsycInfo performed in July 2012, using the subject terms and keywords of 'monoamine oxidase inhibitors', 'major depression', 'depressive disorder' and 'depression (emotion)'...
  12. ncbi Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum
    Angela Groebe
    Faculty of Medicine, Institute of Neuroanatomy, RWTH Aachen University, 52074 Aachen, Germany
    Cerebellum 8:163-74. 2009
    ..Behavioral changes after cuprizone described for this animal model may not only result from effects on commissural fiber tracts but also can arise from cerebellar demyelination...
  13. ncbi Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors
    Tomas Herraiz
    Instituto de Ciencia y Tecnología de Alimentos y Nutrición ICTAN, Spanish Council for Scientific Research CSIC, Juan de la Cierva, Madrid, Spain
    Food Chem Toxicol 49:1773-81. 2011
    ..Methylene blue, 5-nitroindazole, norharman, 9-methylnorharman and menadione inhibit MAO-B in mitochondria and afford protective effects, as suggested by a reduced conversion of MPTP to neurotoxic species...
  14. pmc Microglial recruitment, activation, and proliferation in response to primary demyelination
    Leah T Remington
    Montreal Neurological Institute, McGill University, Montreal, Canada
    Am J Pathol 170:1713-24. 2007
    ..Our study highlights the role of microglia as a heterogeneous population of cells in primary demyelination, with the capacity to present antigen, proliferate, and migrate into demyelinated areas...
  15. ncbi Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats
    S Eliash
    Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel
    J Neural Transm 108:909-23. 2001
    ..The drugs were equipotent when they were given at a ratio of 1:2. The mechanism has yet to be elucidated. The differential effects of the drugs on blood pressure and MAO inhibition rule out either effect as the sole explanation...
  16. ncbi Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications
    Min Gyu Lee
    The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, USA
    Chem Biol 13:563-7. 2006
    ..Here we show that in contrast to selective monoamine oxidase inhibitors such as pargyline, nonselective monoamine oxidase inhibitors potently inhibit nucleosomal demethylation ..
  17. pmc Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
    Natalie J Ives
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2RR
    BMJ 329:593. 2004
    ..To quantify more reliably the benefits and risks of monoamine oxidase type B inhibitors (MAOBIs) in early Parkinson's disease...
  18. ncbi Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
    Matthew B Stern
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 19:916-23. 2004
    ..05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD...
  19. ncbi Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class
    Claudia Binda
    Department of Genetics and Microbiology, University of Pavia, via Abbiategrasso 207, Pavia, 27100 Italy
    J Med Chem 47:1767-74. 2004
    ..These structural studies may guide future drug design to improve selectivity and efficacy by introducing appropriate substituents on the rasagiline molecular scaffold...
  20. ncbi Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
    P K Gillman
    Pioneer Valley Private Hospital, Mackay, Queensland, Australia
    Br J Anaesth 95:434-41. 2005
    ..Morphine, codeine, oxycodone and buprenorphine are known not to be SRIs, and do not precipitate serotonin toxicity with MAOIs...
  21. pmc Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity
    C B Seymour
    Radiation and Environmental Science Centre, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland
    Br J Cancer 89:1979-86. 2003
    ..This hypothesis is supported by data showing reduced levels of apoptosis in HaCAT cells and in normal bladder explant cultures following treatment with l-deprenyl...
  22. ncbi Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats
    Ryan M Franke
    Department of Pharmacology, School of Medicine, University of California, Irvine CA, 92697, USA
    Psychopharmacology (Berl) 195:117-24. 2007
    ..Although gestational nicotine (GN) treatment in rodents is used as the primary animal model of maternal smoking, tobacco smoke contains more than 4,000 constituents, including monoamine oxidase inhibitors (MAOIs).
  23. ncbi Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential
    Simone Carradori
    Sapienza University of Rome, Department of Drug Chemistry and Technologies, P le Aldo Moro 5, 00185 Rome, Italy
    Expert Opin Ther Pat 22:759-801. 2012
    ..As a consequence of this, the development of human MAO inhibitors led to important discoveries in the treatment of several neuropsychiatric and neurodegenerative disorders...
  24. ncbi A double-blind, delayed-start trial of rasagiline in Parkinson's disease
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    N Engl J Med 361:1268-78. 2009
    ..A therapy that slows disease progression is the major unmet need in Parkinson's disease...
  25. ncbi Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors
    Peter Kenneth Gillman
    MRCPsych, PO Box 86, Bucasia, Queensland 4750, Australia
    J Clin Psychopharmacol 31:66-74. 2011
    Recent advances clarifying the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors that have not been considered in depth lately are discussed...
  26. ncbi Monoamine oxidase inhibitors and neuroprotection: a review
    Saleem K Al-Nuaimi
    Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    Am J Ther 19:436-48. 2012
    b>Monoamine oxidase inhibitors have been available for more than 50 years, initially developed as antidepressants but currently used in a variety of psychiatric and neurological conditions...
  27. ncbi Binding of sigma-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of sigma-receptor subtypes
    Y Itzhak
    Department of Biochemistry and Molecular Biology, REPSCEND Laboratories, University of Miami School of Medicine, Florida 33101
    J Pharmacol Exp Ther 257:141-8. 1991
    ..abstract truncated at 250 words)..
  28. pmc Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination
    J P Buschmann
    Institute of Neuroanatomy, Faculty of Medicine, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
    J Mol Neurosci 48:66-76. 2012
    ..The same holds true for the expression of the key chemokines Ccl2 and Ccl3. The current study defines a model to study early microglia activation and to investigate differences in the neuroinflammatory response of white vs. gray matter...
  29. pmc Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior?
    Alan G Mallinger
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Psychopharmacol Bull 42:64-74. 2009
    ..We report here a comparison of monoamine oxidase inhibitors (MAOIs) with the serotonin reuptake inhibitor paroxetine (PAROX).
  30. ncbi Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease
    F Stocchi
    Institute of Neurology, IRCCS Neuromed, Pozzilli, Italy
    Int J Clin Pract 60:215-21. 2006
    ....
  31. ncbi Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B
    Claudia Binda
    Department of Genetics and Microbiology, University of Pavia, Via Ferrata 1, Pavia 27100, Italy
    Biochemistry 47:5616-25. 2008
    ..The bound arylalkyl radical reacts with the N(5) of the flavin, while the dissociated diazene reacts nonspecifically with the enzyme through arylalkylradicals...
  32. pmc Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis
    Jin Wang
    Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322, United States
    Biochemistry 50:2499-505. 2011
    ..The differential mitochondrial outer membrane topology of MAO A and MAO B is relevant to their inhibition by drugs designed to be cardioprotectants or neuroprotectants...
  33. ncbi Monoamine oxidase inhibitors for IgA nephropathy
    E L Altschuler
    Brain and Perception Laboratory, University of California, San Diego, 9500 Gilman Drive, 0109, La Jolla, CA 92093 0109, USA
    Med Hypotheses 56:225-6. 2001
    ..Increased monoamine levels, via increased cellular cyclic AMP, can decrease TNF elaboration. Monoamine oxidase inhibitors (MAO-Is) have been found effective in case studies for a number of diseases, e.g...
  34. ncbi Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease
    David R P Guay
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Am J Geriatr Pharmacother 4:330-46. 2006
    ....
  35. ncbi Neuroprotection by rasagiline in thiamine deficient rats
    Sarah Eliash
    Dept of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv 69978, Israel
    Brain Res 1256:138-48. 2009
    ..These findings demonstrate significant neuroprotection by rasagiline with possible implications for clinical neurodegenerative disorders...
  36. ncbi Monoamine oxidase inhibitors. A perspective on their use in the elderly
    H P Volz
    Hans Berger Kliniken, Klinik fur Psychiatrie, Friedrich Schiller Universitat Jena, Germany
    Drugs Aging 13:341-55. 1998
    b>Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease...
  37. ncbi The transdermal delivery system of monoamine oxidase inhibitors
    Chad M VanDenBerg
    Department of Pharmacy Practice and Center for Clinical Research, Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, USA
    J Clin Psychiatry 73:25-30. 2012
    b>Monoamine oxidase inhibitors (MAOIs) were once widely used as effective treatments for major depressive disorder, particularly for patients with atypical or treatment-resistant depression...
  38. doi Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics
    Peter Fangmann
    LWL Klinik Bochum, Department of Psychiatry, Psychotherapy, Psychosomatic and Preventive Medicine, Ruhr University Bochum, Bochum, Germany
    J Clin Psychopharmacol 28:1-4. 2008
  39. ncbi Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors
    Marcelo Vilches-Herrera
    Department of Chemistry, Faculty of Sciences, University of Chile, Casilla 653, Santiago, Chile
    Bioorg Med Chem 17:2452-60. 2009
    A series of naphthylisopropylamine and N-benzyl-4-methylthioamphetamine derivatives were evaluated as monoamine oxidase inhibitors. Their potencies were compared with those of a series of amphetamine derivatives, to test if the increase ..
  40. ncbi Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors
    J Reniers
    Drug Design and Discovery Center, Laboratoire de Chimie Biologique Structurale, Facultes Universitaires Notre Dame de la Paix, Namur, Belgium
    Bioorg Med Chem 19:134-44. 2011
    ..6nM. This cyclohexyl bearing analogue is also a potent MAO-A inhibitor with a K(i) value of 4.3nM. Molecular docking studies show that the cyclohexyl chain also occupies a hydrophobic pocket but in different ways in MAO-A or MAO-B...
  41. pmc Brain monoamine oxidase A activity predicts trait aggression
    Nelly Alia-Klein
    Medical Department, Brookhaven National Laboratory, Upton, New York 11973, USA
    J Neurosci 28:5099-104. 2008
    ..Because trait aggression is a measure used to predict antisocial behavior, these results underscore the relevance of MAO A as a neurochemical substrate of aberrant aggression...
  42. pmc Brain monoamine oxidase A inhibition in cigarette smokers
    J S Fowler
    Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973 5000, USA
    Proc Natl Acad Sci U S A 93:14065-9. 1996
    ..This suggests that MAO A inhibition needs to be considered as a potential contributing variable in the high rate of smoking in depression and in the development of more effective strategies for smoking cessation...
  43. ncbi Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
    Claudia Binda
    Department of Genetics and Microbiology, University of Pavia, Pavia, Italy
    Nat Struct Biol 9:22-6. 2002
    ..The structure provides a framework for probing the catalytic mechanism, understanding the differences between the B- and A-monoamine oxidase isoforms and designing specific inhibitors...
  44. ncbi Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives
    Silvia Mandel
    Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research, Israel
    Brain Res Brain Res Rev 48:379-87. 2005
    ..The neuroprotective activity of propargylamine has led us to develop novel bifunctional neuroprotective iron-chelating MAO-inhibiting drugs possessing propargyl moiety for the treatment of other neurodegenerative diseases...
  45. ncbi Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination
    Maren Lindner
    Department of Neurology, Hannover Medical School, Hannover, Germany
    Neurosci Lett 453:120-5. 2009
    ..These data suggest that two pattern of axonal injury occur in the cuprizone model...
  46. ncbi Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
    F Blandini
    Laboratory of Functional Neurochemistry, Neurological Institute C Mondino, 27100, Pavia, Italy
    Exp Neurol 187:455-9. 2004
    ..Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD)...
  47. ncbi Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies
    Claudia Binda
    Dept Genetics and Microbiology, University of Pavia, Via Ferrata 1, 27100 Pavia, Italy
    Curr Top Med Chem 11:2788-96. 2011
    ..This multi-target approach may prove successful in order to find new and more effective therapies for the complexity of neurodegenerative diseases...
  48. ncbi The pharmacology of selegiline
    Kálmán Magyar
    Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary
    Int Rev Neurobiol 100:65-84. 2011
    ..To circumvent the "first pass" metabolism, parenteral administration of the drug might lead to different distribution and pharmacological activity of selegiline...
  49. pmc Platelet-derived growth factor promotes repair of chronically demyelinated white matter
    Adam C Vana
    Department of Anatomy, Physiology, and Genetics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 4799, USA
    J Neuropathol Exp Neurol 66:975-88. 2007
    ..Furthermore, preventing oligodendrocyte apoptosis may be important not only during active demyelination but also for supporting the generation of new oligodendrocytes to remyelinate chronic lesions...
  50. ncbi Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors
    C Carpene
    Institut National de la Sante et de la Recherche Medicale, INSERM U858 équipe 3, F 31432 Toulouse, France
    Pharmacol Res 57:426-34. 2008
    ..These observations suggest that SSAO inhibition is not sufficient to impair fat deposition. However, combined MAO and SSAO inhibition limits adiposity in non-obese as well as in obese rats...
  51. ncbi A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
    A Clarke
    Scherer DDS, Swindon, United Kingdom
    J Neural Transm 110:1257-71. 2003
    ....
  52. ncbi Protection against apoptosis by monoamine oxidase A inhibitors
    W Malorni
    Department of Ultrastructures, Istituto Superiore di Sanita, Rome, Italy
    FEBS Lett 426:155-9. 1998
    ..These data represent the first demonstration that MAO-A inhibitors may protect cells from apoptosis through a mechanism involving the maintenance of mitochondrial homeostasis...
  53. ncbi Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders
    Makoto Naoi
    Department of Neurosciences, Gifu International Institute of Biotechnology, 1 1 Nakafudogaoka, Kakamigahara, Gifu 504 0838, Japan
    Curr Pharm Des 16:2799-817. 2010
    ..This review presents the molecular mechanisms behind neuroprotection by monoamine oxidase inhibitors and discusses the possible development of new drugs to prevent, delay and restore the neuronal cell ..
  54. pmc Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B
    Luigi De Colibus
    Department of Genetics and Microbiology, University of Pavia, via Abbiategrasso 207, 27100 Pavia, Italy
    Proc Natl Acad Sci U S A 102:12684-9. 2005
    ..M., Soldevila, M., Navarro, A., Kidd, K. K., Oliva, B. & Bertranpetit, J. (2004) Hum. Genet. 115, 377-386]. These considerations put into question the use of MAO A from nonhuman sources in drug development for use in humans...
  55. ncbi Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
    Jack J Chen
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Clin Ther 29:1825-49. 2007
    ..Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD)...
  56. ncbi Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline
    A Kupsch
    Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, and Institute of Physiology, Munchen, Federal Republic of Germany
    J Neural Transm 108:985-1009. 2001
    ..It remains to be determined, if this histological observation represents potential adverse effects of high dose treatment with monoamine oxidase inhibitors.
  57. ncbi Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells
    Saleh Abu-Raya
    Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem 91120, Israel
    Eur J Pharmacol 434:109-16. 2002
    ..These results suggest there may be a neuroprotective advantage of rasagiline over selegiline...
  58. ncbi Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]
    Sevil Yasar
    Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 317:387-94. 2006
    ....
  59. ncbi Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains
    Makoto Naoi
    Department of Brain Sciences, Institute of Applied Biochemistry, Yagi Memorial Park, Matake, Gifu 505 0116, Japan
    Neurotoxicology 25:193-204. 2004
    ..These results are discussed in relation to role of dopamine-derived endogenous salsolinol derivatives as the regulators of neurotransmission, dopaminergic neurotoxins and neuro-hormonal transmitters in the human brain...
  60. ncbi The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo
    M B Youdim
    Technion Faculty of Medicine, Eve Topf and NPF Neurodegenerative Disease Centers, Efron Street, Bat Galim, Haifa, Israel
    Ann N Y Acad Sci 939:450-8. 2001
    ....
  61. ncbi Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline
    Tamar Goren
    Teva Pharmaceutical Industries Ltd, PO Box 8077 Kiryat Nordau, Netanya, Israel
    J Clin Pharmacol 50:1420-8. 2010
    ..These data allowed removal of dietary tyramine restriction from rasagiline US labeling...
  62. ncbi Antidepressant-like effects of selegiline in the forced swim test
    Seiichiro Shimazu
    Research Institute, Fujimoto Pharmaceutical Corporation, 1 3 40 Nishiotsuka, Matsubara, Osaka 580 0011, Japan
    Eur Neuropsychopharmacol 15:563-71. 2005
    ..These results suggest that selegiline exerts the antidepressant-like effects by prolonging escape-directed behavior rather than by a motor stimulant effect and D1 receptor activation contributes to its effect...
  63. ncbi Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors
    J Bergman
    Harvard Medical School, McLean Hospital ADARC, 115 Mill Street, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 159:21-30. 2001
    ..The present experiments were conducted to study how the discriminative-stimulus (S(D)) and reinforcing-stimulus (S(R)) effects of beta-PEA in monkeys are modified by treatment with inhibitors of MAO-B [R-(-)-deprenyl and MDL 72974]...
  64. ncbi Monoamine oxidase and cigarette smoking
    Joanna S Fowler
    Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    Neurotoxicology 24:75-82. 2003
    ....
  65. ncbi Inhibition of monoamine oxidase B in the brains of smokers
    J S Fowler
    Brookhaven National Laboratory, Upton, New York 11973, USA
    Nature 379:733-6. 1996
    ..We propose that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking...
  66. pmc The role of monoamine oxidase inhibitors in current psychiatric practice
    Jess G Fiedorowicz
    The Johns Hopkins Hospital, Dept of Psychiatry, Baltimore, MD 21287 7131, USA
    J Psychiatr Pract 10:239-48. 2004
    The use of monoamine oxidase inhibitors (MAOIs) by psychiatrists has declined over the past several decades with the expansion of psychiatrists' pharmacologic armamentarium...
  67. ncbi Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence
    Ahmed Elkashef
    National Institute on Drug Abuse NIDA, Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMCDA, MSC 9551 Bethesda, MD 20892, USA
    Drug Alcohol Depend 85:191-7. 2006
    ..The contrast of this result to earlier, promising preclinical and human pilot data could be due to factors associated with sample size, patient characteristics, dose, or poor predictive validity of preclinical models...
  68. ncbi Toxicokinetic evaluation of a selegiline transdermal system in the dog
    J S Barrett
    Somerset Pharmaceuticals, Tampa, FL, USA
    Biopharm Drug Dispos 18:165-84. 1997
    ..15 mg kg-1 d-1), documents the safety of the selegiline drug substance and indicates that additional toxicologic findings with the STS may not be expected...
  69. ncbi A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease
    Moussa B H Youdim
    Department of Pharmacology, Technion Bruce Rappaport Faculty of Medicine, Eve Topf and NPF Neurodegenerative Diseases Centers, Rappaport Family Research Institute, Haifa, Israel
    Neurology 63:S32-5. 2004
  70. ncbi Tranylcypromine enhancement of nicotine self-administration
    Anne Sophie Villegier
    Department of Pharmacology, School of Medicine, University of California, Irvine, CA 92697, USA
    Neuropharmacology 52:1415-25. 2007
    ..Taken together, these results indicate that in a stringent self-administration acquisition test, MAO inhibition increases the rewarding effect of low doses of nicotine, possibly via a dopamine-dependent mechanism...
  71. pmc Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
    Adam L Halberstadt
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093 0804, USA
    Psychopharmacology (Berl) 201:55-66. 2008
    ....
  72. ncbi Transdermal selegiline and intravenous cocaine: safety and interactions
    Elisabeth J Houtsmuller
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Bayview Medical Center, 5510 Nathan Shock Drive, Baltimore, MD 21224 6823, USA
    Psychopharmacology (Berl) 172:31-40. 2004
    ..Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests selegiline may modify subjective effects of cocaine...
  73. ncbi Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors
    Anne Sophie Villegier
    INSERM U 114, College de France, 11, place Marcelin Berthelot, 75231 Paris Cedex 05, France
    Pharmacol Biochem Behav 76:267-74. 2003
    ..Since tobacco smoke is known to contain many compounds including MAOIs, our data suggest that addictive properties of tobacco may not be limited to nicotine. We propose that MAOIs potentiate effects of nicotine on monoamines release...
  74. ncbi Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
    ..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
  75. ncbi 2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action
    P R Paetsch
    Department of Psychiatry, University of Alberta, Edmonton, Canada
    Neurochem Res 18:1015-22. 1993
    ..MAOI antidepressants induced a decrease in the density of both D1-like and D2-like DA receptors. These data are discussed in terms of a possible role of PEA-catecholamine interactions in antidepressant drug action...
  76. ncbi Transdermal selegiline: targeted effects on monoamine oxidases in the brain
    Lynn Wecker
    Department of Pharmacology and Therapeutics, University of South Florida College of Medicine, Tampa, Florida 33612 4799, USA
    Biol Psychiatry 54:1099-104. 2003
    ..These studies determined whether the transdermal administration of selegiline has differential effects on MAOs in brain versus the gastrointestinal system...
  77. ncbi Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication
    S Shalom Feinberg
    Department of Psychiatry, Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Psychiatry 65:1520-4. 2004
    ..Despite that fact, experienced clinicians continue to use this combination for a variety of indications after other options have failed. This article reviews these reported uses and presents a case suggesting another possible indication...
  78. ncbi Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor
    John J Thébault
    Ges, Brussels, Belgium
    Pharmacotherapy 24:1295-305. 2004
    ..To investigate the tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline after once-daily oral administration of single or repeated doses...
  79. ncbi In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET
    Nanette M T Freedman
    Department of Medical Biophysics and Nuclear Medicine, Hadassah University Hospital, Jerusalem, Israel
    J Nucl Med 46:1618-24. 2005
    ..In this study, we used (11)C-l-deprenyl PET to demonstrate the specific binding characteristics of the new irreversible selective MAO-B inhibitor rasagiline in 3 healthy volunteers...
  80. ncbi Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors
    Claire Henchcliffe
    Weill Medical College of Cornell University, Department of Neurology and Neuroscience, 428 East 72, Street, Suite 400, NY 10021, USA
    Expert Rev Neurother 5:811-21. 2005
    b>Monoamine oxidase inhibitors inhibit dopamine metabolism and are therefore effective in treating Parkinson's disease, a condition associated with progressive striatal dopamine deficiency secondary to degeneration of dopaminergic neurons ..
  81. ncbi Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine
    Anne Sophie Villegier
    INSERM U 114, College de France
    Neuropsychopharmacology 31:1704-13. 2006
    ..Because tobacco smoke contains monoamine oxidase inhibitors (MAOIs) and decreases MAO activity in smokers, we have combined MAOIs with nicotine to determine ..
  82. ncbi Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats
    Takeshi Izumi
    Department of Psychiatry, Hokkaido University Graduate School of Medicine, North 15, West 7, Sapporo 060 8638, Japan
    Eur J Pharmacol 532:258-64. 2006
    ..These data suggest that non-selective MAO and selective MAO-A inhibitors can induce 5-HT syndrome in humans when co-administered with SSRI. Further, the risk of 5-HT syndrome may be lower with the selective MAO-B inhibitor, selegiline...
  83. ncbi Monoamine oxidase and tobacco dependence
    A Lewis
    Institute of Environmental Science and Research Ltd, 34 Kenepuru Drive, P O Box 50 348, Porirua, Wellington, New Zealand
    Neurotoxicology 28:182-95. 2007
    ..This article provides a review of the current knowledge of the association between MAO and tobacco dependence and suggests that further research into this topic is likely to lead to more effective pharmacotherapies for smoking cessation...
  84. ncbi The influence of metabolism on the MAO-B inhibitory potency of selegiline
    D Haberle
    Department of Pharmacodynamics Semmelweis University, H 1445 Budapest, Hungary
    Curr Med Chem 9:47-51. 2002
    ..The parent compound is responsible for the inhibition of MAO-B enzyme activity...
  85. pmc Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway
    Nicholas Macinnes
    Wolfson Centre for Age Related Diseases, G20 Wolfson Wing, Hodgkin Building, Guy s Campus, GKT School of Biomedical Sciences, King s College London, London SE1 1UL, UK
    Br J Pharmacol 143:952-9. 2004
    ....
  86. ncbi Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats
    Tomohiro Tatsuta
    Department of Pharmacology, Hyogo College of Medicine, 1 1 Mukogawa cho, Nishinomiya, 663 8501, Hyogo, Japan
    Neurochem Res 30:1377-85. 2005
    ..These results suggest that a low dose of clorgyline tends to increase the latency and decrease the intensity of stereotypies induced by METH in a dopamine metabolism-independent manner in mice...
  87. ncbi Predictors of response to monoamine oxidase inhibitors: do they exist?
    J R Davidson
    Duke University Medical Center, Durham, NC 27710
    Eur Arch Psychiatry Clin Neurosci 241:181-6. 1991
    Multiple regression analysis was conducted on potential response predictors in a double-blind study of monoamine oxidase inhibitors (MAOI) and placebo treatment in 130 depressed outpatients...
  88. ncbi Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms
    Anup K Upadhyay
    Department of Biochemistry, Emory University, Atlanta, Georgia 30322, USA
    Biochemistry 47:526-36. 2008
    ....
  89. ncbi A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition
    A Clarke
    Scherer DDS, Swindon, United Kingdom
    J Neural Transm 110:1241-55. 2003
    ..25 mg, which is associated with lower concentrations of potentially harmful metabolites, could offer a safer and more predictable treatment in the management of patients with Parkinson's disease...
  90. ncbi Molecular characterization of monoamine oxidase in zebrafish (Danio rerio)
    Andrea Setini
    Department of Animal and Human Biology, University of Rome I, Viale dell Universita, 32, Rome 00185, Italy
    Comp Biochem Physiol B Biochem Mol Biol 140:153-61. 2005
    ..Experiments performed to test the effect of selective MAO A (clorgyline) and MAO B (deprenyl) inhibitors on the enzyme's activity in liver and brain confirm the presence of a single form of MAO in zebrafish...
  91. ncbi [The effect of long-term administration of isatin and himantan to mice on sensitivity of brain monoamine oxidase B to inhibition by deprenyl in vivo and in vitro]
    E A Val'dman
    Biomed Khim 50:509-13. 2004
    ..The latter suggests that long-term treatment of animals with reversible easily dissociating inhibitors may influence regulatory properties of MAO B...
  92. pmc A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys
    Sevil Yasar
    Preclinical Pharmacology Section, Behavioral Neurosciences Research Branch, DHHS NIH NIDA Intramural Research Program, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 183:413-21. 2006
    ..Under conditions where drug-seeking and drug-taking behaviors are actively maintained by D-amphetamine, L-deprenyl, at doses that specifically inhibit type B monoamine oxidase, may not be effective as a treatment...
  93. ncbi Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases
    M B H Youdim
    Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, and Department of Pharmacology, Technion Rapapport Faculty of Medicine, Haifa, Israel
    J Neural Transm 111:1455-71. 2004
    ..We have now developed several of these compounds with neuroprotective, MAO inhibitory and iron chelating properties from our prototype iron chelators, VK-28 possessing propargylamine moiety of our anti-parkinson drug, rasagiline...
  94. ncbi Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells
    Thomas Muller
    Department of Neurology, St Josef Hospital, University of Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Neurol Res 30:417-9. 2008
    ..Clinically, our findings support an early start of long-term treatment with selegiline in view of the various neurotoxin hypotheses and mechanisms of neuronal death in chronic neurodegenerative disorders...
  95. pmc The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
    L P Quinn
    Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK
    Br J Pharmacol 154:226-33. 2008
    ....
  96. pmc Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline
    Zaid A Abassi
    Department of Physiology and Biophysics, Technion Rappaport Faculty of Medicine and Rappaport Family Institute for Research in the Medical Sciences, Technion, Haifa, Israel
    Br J Pharmacol 143:371-8. 2004
    ..These findings indicate that rasagiline, when given at doses equivalent to selegiline, is less likely to be hypotensive...
  97. ncbi Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant
    Mona Seif-el-Nasr
    Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
    Arzneimittelforschung 58:160-7. 2008
    ....
  98. ncbi 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B
    Sandra L Hrometz
    The Department of Pharmaceutical and Biomedical Sciences, The Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810, USA
    Neurosci Lett 367:56-9. 2004
    ..These findings support the hypothesis that the deamination of DA by MAO-B within the serotonergic cell can lead to hydrogen peroxide formation and ultimately cell death...
  99. ncbi [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]
    Ildiko Miklya
    Semmelweis Egyetem, AOK, Farmakológiai és Farmakoterápiás Intézet, Budapest
    Neuropsychopharmacol Hung 10:15-22. 2008
    ..Thus, rasagiline can not be a substitute for (-)-deprenyl in therapy...
  100. ncbi Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum
    N Kitanaka
    Department of Pharmacology, Hyogo College of Medicine, 1 1 Mukogawa cho, Nishinomiya, Hyogo 663 8501, Japan
    Neuroscience 130:295-308. 2005
    ..These results suggest that clorgyline tends to oppose METH-induced hyperlocomotion through alteration of the serotonergic system in the region of the striatum and accumbens...
  101. ncbi The effect of l-deprenyl on tissue mRNA expressions of NOS isoforms and NO levels in an experimental diabetes mellitus model
    S V Irer
    Department of Biochemistry, Ege University Medical School, Izmir, Turkey
    J Neural Transm 114:811-5. 2007
    ..05). l-Deprenyl, causing a decrease in tissue NOS expressions, might be of benefit by protecting the organism from the toxic radical effects of NO...

Research Grants63

  1. Persistent Attenuation of Cocaine-Reinforced Behavior
    KENNETH W GRASING; Fiscal Year: 2013
    ..Aversive effects of cocaine will be assessed by allowing rats to make mutually-exclusive choices for drug or food reinforcement and measuring their proximity to levers used to obtain either reinforcer. ..
  2. Developing a PET biomarker to predict response in treatment-resistant depression
    PATRICK J MC GRATH; Fiscal Year: 2010
    ....
  3. DRUG TREATMENT OF COEXISTING PANIC AND MAJOR DEPRESSION
    ROBERT LYDIARD; Fiscal Year: 1999
    ..such as imipramine have been more commonly used to treat this disorder, limited data suggest that the monoamine oxidase inhibitors are more effective than tricyclics...
  4. DOES ATYPICAL DEPRESSION RESPOND TO COGNITIVE THERAPY?
    Robin Jarrett; Fiscal Year: 1993
    ..The efficacy of treatment is assessed at randomization, weeks 2,4,8 and 10 or at end-point by a clinical evaluator blind to treatment assignment Multivariate, univariate and post hoc analyses are planned...
  5. Antidepressants - same effect on mesolimbic DA activity?
    JAY WEISS; Fiscal Year: 2009
    ....
  6. PHENELZINE, FLUOXENTINE, PLACEBO TRIAL IN OCD
    Michael Jenike; Fiscal Year: 1991
    There are a growing number of case reports which indicate that monoamine oxidase inhibitors may be helpful in patients with obsessive compulsive disorder (OCD)...
  7. REGULATION OF BRAIN & LYMPHOID GLUCOCORTICOID RECEPTORS
    MARTIN LOWY; Fiscal Year: 1993
    ..treatments (ADT), including monoamine reuptake inhibitors, lithium, electroconvulsive shock monoamine oxidase inhibitors on basal GR measurements will be assessed...
  8. IMPROVED THERAPY FOR DEPRESSION
    Emil Pop; Fiscal Year: 1990
    ..of depression including electroconvulsive therapy and pharmacotherapy mainly by tricyclics and monoamine oxidase inhibitors are totally satisfactory and new drugs are needed...
  9. NUCLEOTIDE CHANGES WITH AGGRESSION-ALTERING DRUGS
    Burr Eichelman; Fiscal Year: 1980
    ..g., 6-hydroxydopamine, monoamine oxidase inhibitors, dibenzazepines, and rubidium) and drugs which have been reported to decrease aggression (beta blockers,..
  10. CBT for Residual ADHD Symptoms in Adults
    Steven Safren; Fiscal Year: 2002
    ....
  11. MPTP INDUCED MODEL OF PARKINSON'S DISEASE
    Madhu Gupta; Fiscal Year: 1991
    ..With this approach, we will establish the extent to which MPTP administration in young and aging mice can be used as a model for anatomical and neurochemical characteristics of Parkinson's disease...
  12. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2004
    ....
  13. Addiction and the Brain: Are We Hard Wired to Abuse Drugs
    Joanna Fowler; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  14. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2002
    ....
  15. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael E Thase; Fiscal Year: 2010
    ....
  16. FLUOXETINE AND BEHAVIOR THERAPY IN SOCIAL PHOBIA
    Jonathan Davidson; Fiscal Year: 2001
    ..Effective treatments can be a long way towards reducing the societal burden associated with the disorder. ..
  17. MAINTENANCE FLUOXETINE IN POSTTRAUMATIC STRESS DISORDER
    Jonathan Davidson; Fiscal Year: 2001
    ..Health services and cost implications of such findings remain considerable, given the morbidity associated with PTSD. ..
  18. KAVA KAVA IN GENERALIZED ANXIETY: A DOUBLE-BLIND TRIAL
    Jonathan Davidson; Fiscal Year: 2001
    ..It will also contribute towards providing an answer to what is rapidly becoming a major public health question, namely what can we reasonably expect herbal treatments to offer? ..
  19. Substance Use Comorbidity Care: Evidence-Based Stepped Strategies for Depression
    Carlos Blanco; Fiscal Year: 2010
    ..abstract_text> ..
  20. Brain DHA, Dopamine, and Behavior: Roles in ADHD
    Beth Levant; Fiscal Year: 2006
    ..Such insights may identify a means by which certain risk factors for ADHD may be reduced or eliminated or the severity of the disease may be reduced through appropriate pre- and postnatal nutrition. [unreadable] [unreadable]..
  21. Brain LC-PUFAs and Maternal Mental Health
    Beth Levant; Fiscal Year: 2006
    ..These findings will also suggest novel treatments for such illnesses when they occur. ..
  22. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  23. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  24. PGP Regulation of Antipsychotic Exposure and Effects
    C Devane; Fiscal Year: 2008
    ..The results of this research will provide support for translational studies in humans to refine treatment guidelines for the use of this class of medications in severely mentally ill patients. ..
  25. SMART: Improving Detection & Outcome of Psychiatric Comorbidity in Drug Treatment
    Carlos Blanco; Fiscal Year: 2010
    ..abstract_text> ..
  26. Improving Outcomes in Pharmacotherapy of Social Phobia
    Mark Pollack; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  27. D-Cycloserine Enhancement of Exposure in Social Phobia
    Mark H Pollack; Fiscal Year: 2010
    ..This study addresses an important public health issue by assessing an intervention that may lead to a more efficient and effective application of empirically based psychosocial interventions for the treatment of SAD. ..
  28. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  29. Screening for comorbidity in substance abuse clinics
    Carlos Blanco; Fiscal Year: 2004
    ..abstract_text> ..
  30. Impact of Trauma of Terroist Attack on Bipolar Patients
    Mark Pollack; Fiscal Year: 2003
    ..abstract_text> ..
  31. Pharmacogenetics of Methadone
    C Devane; Fiscal Year: 2003
    ..This study will form the basis for subsequent studies which should provide a more rational basis for dosing of methadone in pregnant addicts. ..
  32. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  33. MR SPECTROSCOPIC IMAGING DURING METHADONE MAINTENANCE
    Mark Pollack; Fiscal Year: 2002
    ....
  34. Improving Outcomes in Pharmacotherapy of Social Phobia
    Michael Van Ameringen; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  35. DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PD
    C Olanow; Fiscal Year: 2003
    ..abstract_text> ..
  36. Emory Conte Center for the Neuroscience of Mental Disorders
    Becky Kinkead; Fiscal Year: 2008
    ..abstract_text> ..
  37. Preventing Psychiatric Sequelae of Traumatic Injury
    Murray Stein; Fiscal Year: 2003
    ..Findings will provide justification for and information about optimal parameters (e.g., subject selection; sample size; dose and duration) for a future randomized controlled trial (RCT). ..
  38. Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay
    Murray Stein; Fiscal Year: 2008
    ..Enhancing the development of new treatments for anxiety is a public health priority. The projects proposed in this application have the potential to achieve this important aim. [unreadable] [unreadable] [unreadable]..
  39. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2003
    ....
  40. Improving Outcomes in Pharmacotherapy of Social Phobia
    Murray Stein; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  41. Combining Antidepressants to Hasten Remission from Depression
    Jonathan W Stewart; Fiscal Year: 2010
    ....
  42. IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE
    Murray Stein; Fiscal Year: 2002
    ..abstract_text> ..
  43. LABORATORY STUDIES ON ETHANOL IN HUMANS
    ELISABETH HOUTSMULLER; Fiscal Year: 2002
    ..More generally, these studies will enhance our understanding of alcoholism and the factors that influence treatment efficacy. ..
  44. Multiple Factors Affecting Placebo Response in PD
    Christopher Goetz; Fiscal Year: 2004
    ..Defining these determinant influences will help enhance placebo responses in clinical practice and control them in clinical trials. ..
  45. Controlled Study of SAMe vs.Escitalopram in Major Depressive Disorder
    Maurizio Fava; Fiscal Year: 2008
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  46. S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
    George Papakostas; Fiscal Year: 2008
    ..It is hoped that this project award will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator in this area. ..
  47. NOVEL LAPSE-RESPONSIVE APPROACH TO SMOKING CESSATION
    ELISABETH HOUTSMULLER; Fiscal Year: 2005
    ..Therapeutic procedures that reduce or reverse the detrimental effects of early lapse, or interrupt the course to relapse could be a significant breakthrough in improving smoking cessation rates. ..
  48. Effects of Chronic Exposure to Smoking Stimuli
    ELISABETH HOUTSMULLER; Fiscal Year: 2004
    ..Novel treatment strategies (e.g., extinction or sensorimotor stimulation replacement therapies), that specifically address the sensorimotor effects of smoking, would be warranted. ..
  49. Southeastern Michigan Parkinson's Disease Program
    Peter LeWitt; Fiscal Year: 2006
    ..This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection. ..
  50. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2003
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  51. Pharmacotherapy for Minor Depression
    Andrew Nierenberg; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  52. AMPHETAMINE-LIKE STIMULANTS: NOREPINEPHRINE & BEHAVIOR
    CRAIG BERRIDGE; Fiscal Year: 2005
    ..Information obtained in these studies may provide insight into mechanisms subserving, and treatment of, stimulant drug abuse. ..
  53. Cocaine Addiction:Medication Strategies and Evalution
    Jack Bergman; Fiscal Year: 2006
    ..abstract_text> ..
  54. Screening Herbs for Drug Interactions
    JOHN MARKOWITZ; Fiscal Year: 2002
    ..Further, the proposed studies will complement existing and future NCCAM studies of agents such as St. John's wort and Gingko biloba. ..
  55. Family-Based Nutrition Intervention for Latino Children
    Joel Killen; Fiscal Year: 2006
    ..Measurements will be collected within one month of completing the interventions and at six months and one year follow-ups. ..
  56. POSTDOCTORAL INTERDISCIPLINARY HIV-AIDS
    Thomas Newton; Fiscal Year: 2003
    ..Each trainee's curriculum is individually designed to meet their needs and the hands-on research experience is tailored to provide experiences needed to develop independent researchers. ..
  57. A1/A2A Receptors and Caffeine Psychostimulation
    Jiang Fan Chen; Fiscal Year: 2009
    ..abstract_text> ..
  58. Role of norepinephrine and the amygdala in drug relapse
    MATTHEW FELTENSTEIN; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  59. CB-1 Antagonists for Cannabis Addiction
    Jack Bergman; Fiscal Year: 2008
    ..Overall, our proposed studies will permit highly significant progress toward the development of novel antagonist-based medications to combat the addictive power of delta9THC. ..
  60. Bioinformatics & identification of cis elements for dopamine gene expression
    Jiang Fan Chen; Fiscal Year: 2008
    ....
  61. MOLECULAR NEUROBIOLOGY OF DEPRESSION
    Richard Shelton; Fiscal Year: 2003
    ..Develop further expertise in basic molecular biological methods; 2. Develop new projects oriented to future funding opportunities; and 3. Continue to mentor the next generation of investigators. ..
  62. Psychosocial Res. to Improve Drug Treatment in Pregnancy
    Kimberly Yonkers; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  63. TLX Ligands in Neural Stem Cells & Neurodegeneration
    Yanhong Shi; Fiscal Year: 2007
    ..Thus, these studies are directly responsive to the NINDS Collaborative Research in Stem Cell Biology. [unreadable] [unreadable] [unreadable]..